What Bioniz Therapeutics does

Bioniz Therapeutics is a private, clinical-stage biotechnology company headquartered in Irvine, California, founded in 2009 by Nazli Azimi, who serves as Founder, President, CEO, and Board Member. The company is focused on the discovery and development of novel small peptides and small molecules for the treatment of autoimmune diseases and cancer, with its therapeutic strategy centered on modulating the common gamma-chain cytokine family, specifically IL-2, IL-15, and IL-21 signaling. These cytokines are implicated in the pathogenesis of autoimmune conditions such as celiac disease, alopecia areata, and refractory inflammatory disorders, as well as in oncology indications including T-cell and NK-cell malignancies, positioning the company at the intersection of immunology and immuno-oncology.

The company's core technology consists of proprietary peptide-based cytokine antagonists and agonists designed to selectively inhibit or mimic the activity of specific cytokines without the broader immunosuppressive effects of existing biologic therapies. This peptide chemistry platform forms the basis of its preclinical and early-clinical pipeline. The value proposition to patients is differentiated, narrow-spectrum immunomodulation; to pharmaceutical partners, the platform offers modular, target-validated assets with potential for partnership or licensing at clinical proof-of-concept.

Bioniz operates a research-driven biotech business model with no disclosed commercial product revenue. Its funding to date totals approximately $14.3 million across three disclosed equity rounds between August 2013 and August 2016, including a $13 million Series A2 led by Takeda Ventures, with Cota Capital and Signatures Capital participating. The company is not publicly listed, employs 11-50 people, and its go-to-market is expected to flow through licensing, co-development, or acquisition by larger pharmaceutical counterparties following clinical validation, rather than through internal commercialization.

Name

Bioniz Therapeutics

Website

https://bioniz.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Bioniz Therapeutics is a private Irvine, California-based biotechnology company founded in 2009 that discovers and develops proprietary small peptides and molecules targeting IL-2, IL-15, and IL-21 cytokine pathways for the treatment of autoimmune diseases and cancer.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Peptide therapeutics
• Autoimmune disease drugs
• Cancer immunotherapy
• Biopharmaceutical R&D
• Small molecule discovery

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Core offering

Bioniz Therapeutics is a biotechnology company that discovers and develops small peptides and molecules intended for the treatment of autoimmune diseases and cancer. The firm operates as a research-stage biopharmaceutical developer, leveraging proprietary peptide discovery capabilities to identify therapeutic candidates targeting cytokine-mediated pathways.

Product overview

Bioniz (bioniz.com) is an Indonesian online gambling content website that publishes articles, reviews, and strategies related to online slot games, lottery (togel), and casino platforms. The site features content about various online gambling platforms including Juliet4d, Obatbet, Albaslot, Dhx4d, and Bmx4d. The content consists of slot game reviews, betting strategies, platform comparisons, and gaming tips. NOTE: The company name 'Bioniz Therapeutics' (a biotechnology company) does not match the actual source content, which is about an online gambling content platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Peptide therapeutic candidates for autoimmune diseases
• Small molecule therapeutics for cancer

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Seven partnerships are on record, tiered minor.

• juliet4dminorOthersSponsorship and partnership relationship. The platform bioniz.com displays juliet4d as a sponsor, with multiple domain links referenced (juliet4d.com, juliet4dcc.co).
• ObatbetminorOthersPlatform referenced extensively in articles for slot gaming content. Multiple articles reference Obatbet as the primary gaming platform.
• Kemenkes (Kementerian Kesehatan)minorOthersListed under Partnership section on bioniz.com. Indonesian Ministry of Health website referenced as partner link.
• Kemenag (Kementerian Agama)minorOthersListed under Partnership section. Indonesian Ministry of Religious Affairs website.
• BKN (Badan Kepegawaian Negara)minorOthersIndonesian State Civil Apparatus Agency referenced as partner link.
• Kemendikbud (Kementerian Pendidikan dan Kebudayaan)minorOthersIndonesian Ministry of Education and Culture referenced as partner.
• Poltekkes KemenkesminorOthersIndonesian Health Polytechnic institutions referenced as partner links.

Recent moves3 records

Expansion highlights2 records

Direct peers

• Protagonist Therapeutics: Clinical-stage peptide platform company developing oral and injectable peptide candidates for hematology and inflammatory/autoimmune disease (e.g., PTG-300, PTG-200). Directly comparable to Bioniz on therapeutic modality (engineered peptides) and target biology (cytokine-driven autoimmune and rare-disease indications).
• Zealand Pharma: Danish peptide-focused biotech with a track record of licensing and developing engineered peptides across metabolic and inflammatory disease. Comparable to Bioniz as a pure-play peptide discovery and engineering platform targeting disease-driving biology.
• Aileron Therapeutics: Clinical-stage biotech developing stabilized alpha-helical peptides for cancer and other diseases. Directly comparable to Bioniz on peptide modality and on the autoimmune/oncology overlap in their stated therapeutic focus.
• DICE Therapeutics (Eli Lilly): Small-molecule and oral peptide platform for autoimmune and inflammatory disease (acquired by Eli Lilly in 2023). Highly comparable to Bioniz's peptide-based autoimmune focus and represents both a peer and a likely strategic acquirer profile.

Broad incumbents

• Ferring Pharmaceuticals: Large specialty biopharma with a deep portfolio of peptide-based therapeutics across reproductive health, gastroenterology, and urology. Comparable to Bioniz as a peptide platform operator with autoimmune/inflammatory adjacency and as a potential strategic acquirer of a small peptide platform.
• Amgen: Global biopharma with large franchises in inflammation/autoimmune disease and a growing interest in peptide modalities and cytokine-targeted therapies. Relevant as a broad incumbent that competes in Bioniz's target indications and is a realistic strategic counterparty.
• Takeda Pharmaceutical Company: Global biopharma with a leading autoimmune/rare-disease franchise and the lead investor in Bioniz's 2016 Series A via Takeda Ventures. Highly relevant as a strategic incumbent both as a competitor in Bioniz's indication space and as the most natural acquirer of a portfolio asset.
• Eli Lilly: Global biopharma with a major autoimmune disease franchise (e.g., Taltz, Olumiant) that acquired DICE Therapeutics to build a peptide/oral-small-molecule autoimmune platform. Relevant as both a competitor and the most likely strategic acquirer profile for Bioniz.

Emerging players

• CytoAgents: Early-stage biotech developing therapeutics to modulate cytokine release in inflammatory disease. Comparable to Bioniz as a small emerging player focused on cytokine biology in autoimmune/inflammatory indications.
• Eligo Bioscience: Biotech developing peptide-based targeted therapeutics, including phage-derived and synthetic peptides, for microbiome- and immune-mediated disease. Comparable to Bioniz as a small emerging peptide therapeutics developer with an autoimmune/inflammation adjacency.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/bionizt

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioniz Therapeutics